EP 3035954 A1 20160629 - COMPOSITION AND VACCINE FOR TREATING PROSTATE CANCER
Title (en)
COMPOSITION AND VACCINE FOR TREATING PROSTATE CANCER
Title (de)
ZUSAMMENSETZUNG UND IMPFSTOFF ZUR BEHANDLUNG VON PROSTATAKREBS
Title (fr)
COMPOSITION ET VACCIN POUR LE TRAITEMENT DU CANCER DE LA PROSTATE
Publication
Application
Priority
- EP 2013002516 W 20130821
- EP 2013002515 W 20130821
- EP 2014002297 W 20140821
- EP 14755332 A 20140821
IPC 8 full level
A61K 39/00 (2006.01)
CPC (source: EP US)
A61K 39/0011 (2013.01 - EP US); A61K 39/00117 (2018.08 - EP US); A61K 39/001193 (2018.08 - EP US); A61K 39/001194 (2018.08 - EP US); A61K 39/001195 (2018.08 - EP US); A61K 2039/53 (2013.01 - EP)
Citation (examination)
- JOHNSON L E ET AL: "Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 3, 16 January 2006 (2006-01-16), pages 293 - 303, XP028010445, ISSN: 0264-410X, [retrieved on 20060116], DOI: 10.1016/J.VACCINE.2005.07.074
- DREICER R ET AL: "MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 27, no. 4, 18 October 2008 (2008-10-18), pages 379 - 386, XP019673837, ISSN: 1573-0646
- See also references of WO 2015024664A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
DOCDB simple family (application)
EP 14755332 A 20140821